reblozyl data is strong. prior auth is killing us.

Company: Bristol Myers Squibb

Posted by HemeOnc_BMS_East_3387 · March 17, 2026

Tags: field, strategy, launch

COMMANDS data is solid.

hematologists are receptive.

one of the actual bright spots.

but payers want ESA failure documented even when the clinical case is clear.

escalated 3 times.

"we're working on it" every time.

need a human not a hotline.

13 upvotes · 5 comments

More from Bristol Myers Squibb